Pfizer's Novel Integrin αvβ8 Antagonist PF-06940434 Granted IND Approval in China for Advanced or Metastatic Solid Tumors

▎Edited by the WuXi AppTec content team

On November 13, Pfizer's Class 1 new drug PF-06940434 injection received tacit approval for clinical trials in China, according to the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).Proposed Development for the Treatment of Patients with Advanced or Metastatic Solid Tumors. Public information shows that this is Pfizer'sIntegrin αvβ8 Antagonist, is currently conducting Phase 1 clinical trials overseas.

Screenshot source:CDE Official Website

Public data shows that integrin αvβ8 is a cell surface protein, and recent studies have found that it plays a significant promoting role in the occurrence and development of tumors. First,Integrinαvβ8Contributes to the migration and invasion of tumor cellsIt can directly interact with proteins in the extracellular matrix, enhancing the cell's ability to adhere to and invade the matrix, thereby promoting tumor spread. Secondly,Integrinαvβ8Can promote the occurrence and development of tumors by activating the transforming growth factor-β (TGF-β) signaling pathway.TGF-β is a key regulatory factor for cell proliferation and differentiation, and the overactivated TGF-β signaling pathway plays a significant promoting role in many types of tumors. Additionally, integrinsαvβ8May also participate in the occurrence and development of tumors through various mechanisms such as affecting the tumor microenvironment, promoting intercellular signal communication, and maintaining cancer stem cells.